1887

Abstract

Non-polio enteroviruses (NPEV) cause significant disease worldwide. Population-based sero-surveillance, by measuring antibodies against specific NPEV types, provides additional information on past circulation and the prediction for future upsurges. Virus neutralisation assays (VNA), the current method of choice for measuring NPEV type specific antibodies, are not entirely standardised. Via the European Non-Polio Enterovirus Network, we organised a VNA quality assessment in which twelve laboratories participated. We provided five echovirus (E) types (E1, E18, E30 G2, E30 G6 and E6) and intravenous immunoglobulins (IVIG) as a sample for the NPEV VNA quality assessment. Differences in VNA protocols and neutralising Ab (nAb) titres were found between the participating laboratories with geometric coefficients of variation ranging from 10.3–62.9 %. Mixed-effects regression analysis indicated a small but significant effect of type of cell line used. Harmonisation of cell line passage number, however, did not improve variation between laboratories. Calibration by making use of a reference sample, reduced variation between laboratories but differences in nAb titres remained higher than two log2 dilution steps. In conclusion, sero-surveillance data from different laboratories should be compared with caution and standardised protocols are needed.

Funding
This study was supported by the:
  • Centrum Infectieziektebestrijding, Rijksinstituut voor Volksgezondheid en Milieu
    • Principle Award Recipient: KimberleyS.M. Benschop
  • Instituto de Salud Carlos III (Award PI18CIII-00017)
    • Principle Award Recipient: MariaCabrerizo
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001986
2024-09-23
2024-11-10
Loading full text...

Full text loading...

References

  1. Brouwer L, Moreni G, Wolthers KC, Pajkrt D. World-wide prevalence and genotype distribution of Enteroviruses. Viruses 2021; 13:434 [View Article] [PubMed]
    [Google Scholar]
  2. Bubba L, Broberg EK, Jasir A, Simmonds P, Harvala H et al. Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infect Dis 2020; 20:350–361 [View Article] [PubMed]
    [Google Scholar]
  3. de Crom SCM, Rossen JWA, van Furth AM, Obihara CC. Enterovirus and parechovirus infection in children: a brief overview. Eur J Pediatr 2016; 175:1023–1029 [View Article] [PubMed]
    [Google Scholar]
  4. Rantakallio P, Leskinen M, von Wendt L. Incidence and prognosis of central nervous system infections in a birth cohort of 12,000 children. Scand J Infect Dis 1986; 18:287–294 [View Article] [PubMed]
    [Google Scholar]
  5. Meijer A, van der Sanden S, Snijders BEP, Jaramillo-Gutierrez G, Bont L et al. Emergence and epidemic occurrence of enterovirus 68 respiratory infections in The Netherlands in 2010. Virology 2012; 423:49–57 [View Article] [PubMed]
    [Google Scholar]
  6. González-Sanz R, Casas-Alba D, Launes C, Muñoz-Almagro C, Ruiz-García MM et al. Molecular epidemiology of an enterovirus A71 outbreak associated with severe neurological disease, Spain, 2016. Euro Surveill 2019; 24:1800089 [View Article] [PubMed]
    [Google Scholar]
  7. Aliabadi N, Messacar K, Pastula DM, Robinson CC, Leshem E et al. Enterovirus D68 infection in children with acute flaccid myelitis, Colorado, USA, 2014. Emerg Infect Dis 2016; 22:1387–1394 [View Article]
    [Google Scholar]
  8. Casas-Alba D, de Sevilla MF, Valero-Rello A, Fortuny C, García-García J-J et al. Outbreak of brainstem encephalitis associated with enterovirus-A71 in Catalonia, Spain (2016): a clinical observational study in a children’s reference centre in Catalonia. Clin Microbiol Infect 2017; 23:874–881 [View Article] [PubMed]
    [Google Scholar]
  9. Grapin M, Mirand A, Pinquier D, Basset A, Bendavid M et al. Severe and fatal neonatal infections linked to a new variant of echovirus 11, France, July 2022 to April 2023. Euro Surveill 2023; 28:22 [View Article]
    [Google Scholar]
  10. Fischer TK, Simmonds P, Harvala H. The importance of enterovirus surveillance in a post-polio world. Lancet Infect Dis 2022; 22:e35–e40 [View Article] [PubMed]
    [Google Scholar]
  11. Harvala H, Benschop KSM, Berginc N, Midgley S, Wolthers K et al. European non-polio enterovirus network: introduction of hospital-based surveillance network to understand the true disease burden of non-polio enterovirus and parechovirus infections in Europe. Microorganisms 2021; 9:1827 [View Article] [PubMed]
    [Google Scholar]
  12. Pons-Salort M, Grassly NC. Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses. Science 2018; 361:800–803 [View Article] [PubMed]
    [Google Scholar]
  13. Karelehto E, Koen G, Benschop K, van der Klis F, Pajkrt D et al. Enterovirus D68 serosurvey: evidence for endemic circulation in the Netherlands, 2006 to 2016. Euro Surveill 2019; 24:35 [View Article] [PubMed]
    [Google Scholar]
  14. Westerhuis B, Kolehmainen P, Benschop K, Nurminen N, Koen G et al. Human parechovirus seroprevalence in Finland and the Netherlands. J Clin Virol 2013; 58:211–215 [View Article] [PubMed]
    [Google Scholar]
  15. Couderé K, van der Straten K, Brouwer L, Koen G, van Eijk H et al. Neutralising antibodies against enterovirus and parechovirus in IVIG reflect general circulation: a tool for sero-surveillance. Viruses 2021; 13:1028 [View Article] [PubMed]
    [Google Scholar]
  16. Kamau E, Harvala H, Blomqvist S, Nguyen D, Horby P et al. Increase in enterovirus D68 infections in young children, United Kingdom, 2006-2016. Emerg Infect Dis 2019; 25:1200–1203 [View Article] [PubMed]
    [Google Scholar]
  17. Zhu R, Cheng T, Yin Z, Liu D, Xu L et al. Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerg Microbes Infect 2018; 7:2 [View Article] [PubMed]
    [Google Scholar]
  18. Kamau E, Bessaud M, Majumdar M, Martin J, Simmonds P et al. Estimating prevalence of Enterovirus D111 in human and non-human primate populations using cross-sectional serology. J Gen Virol 2023; 104:11 [View Article] [PubMed]
    [Google Scholar]
  19. Rosenfeld AB, Shen EQL, Melendez M, Mishra N, Lipkin WI et al. Cross-reactive antibody responses against nonpoliovirus Enteroviruses. mBio 2022; 13:e0366021 [View Article] [PubMed]
    [Google Scholar]
  20. R Core Team Vienna, Austria; R Foundation for Statistical Computing; 2020 https://www.R-project.org/
  21. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493–497 [View Article]
    [Google Scholar]
  22. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill 2021; 26:27 [View Article] [PubMed]
    [Google Scholar]
  23. Khoury DS, Wheatley AK, Ramuta MD, Reynaldi A, Cromer D et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol 2020; 20:727–738 [View Article] [PubMed]
    [Google Scholar]
  24. Manenti A, Molesti E, Maggetti M, Torelli A, Lapini G et al. The theory and practice of the viral dose in neutralization assay: insights on SARS-CoV-2 “doublethink” effect. J Virol Methods 2021; 297:114261 [View Article] [PubMed]
    [Google Scholar]
  25. Cooper G. Report of the WHO collaborative study to establish the 1st WHO International Standard for anti-EV71 serum (Human). WHO/BS/2015.2267; 2018
  26. Crawt L. Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV). WHO/BS/2018.2338; 2018
/content/journal/jgv/10.1099/jgv.0.001986
Loading
/content/journal/jgv/10.1099/jgv.0.001986
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error